We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
Consumption of potentially hepatotoxic drugs was also quantified.
2
Clinicians should be aware of the potential non-antiretroviral hepatotoxic agents that are frequently administered in HIV management.
3
Some potential causes of hepatic dysfunction are viral infections, alcohol and substance abuse, and hepatotoxic drugs such as HAART.
4
The main cause of liver involvement in SLE patients is previous treatment with hepatotoxic drugs or hepatotropic viral hepatitis.
5
Since, the liver and kidneys are the target organs of this fungicide, potential hepatotoxic and nephrotoxic effects are of high relevance.
6
At a dietary level of 8%, both types of culture material were hepatotoxic and caused 100% mortality.
7
To date, the newer thiazolidinediones do not appear to share the hepatotoxic potential of troglitazone, although a few reports of acute hepatitis have accrued.
8
Moreover, no significant hepatotoxic effect was observed in TSA2 groups in doses ranging from 0.05 mg to 0.8 mg.
9
Transaminitis may be more likely to occur in the elderly, in patients receiving concurrent potentially hepatotoxic medications, and possibly with the newer long-acting NSAIDs.
10
To date there is no safety information about long term use of Ageratum conyzoides which contains pyrrolizidine alkaloids, a class of hepatotoxic and carcinogenic phytochemicals.
11
Hepatotoxic adverse drug reactions have contributed to the decline of many promising therapies, even among mainstream medication classes (bromfenac and troglitazone are recent examples).
12
Consumption of potentially hepatotoxic drugs was also quantified.
13
Clinicians should be aware of the potential non-antiretroviral hepatotoxic agents that are frequently administered in HIV management.
14
Some potential causes of hepatic dysfunction are viral infections, alcohol and substance abuse, and hepatotoxic drugs such as HAART.
15
The main cause of liver involvement in SLE patients is previous treatment with hepatotoxic drugs or hepatotropic viral hepatitis.
16
Since, the liver and kidneys are the target organs of this fungicide, potential hepatotoxic and nephrotoxic effects are of high relevance.